Alzheon, Inc. announced the appointment of Susan Abushakra, M.D., as Chief Medical Officer. Dr. Abushakra brings 15 years of neurological drug development expertise to Alzheon. Dr. Abushakra was most recently the Chief Medical Officer at Transition Therapeutics, and prior to that at Elan/Perrigo, where she led the development of ELND005, an amyloid targeting small molecule being developed for neuropsychiatric symptoms in Alzheimer's disease and in Down syndrome.

Previously, Dr. Abushakra was Vice President of Clinical Development at Elan Corporation and Allergan.